Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study
Ohad Atia, Zivia Shavit-Brunschwig, Diane R. Mould, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 31-42
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study
Ohad Atia, Zivia Shavit-Brunschwig, Raffi Lev‐Tzion, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 1
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
Ronen Stein, Dan Turner, Séamus Hussey, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 1
Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Shlomi Cohen, Helena Rolandsdotter, Kaija-Leena Kolho, et al.
Pediatric Drugs (2024) Vol. 26, Iss. 5, pp. 609-617
Open Access | Times Cited: 7
Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease
Patrick Rowland, Megan McNicol, Ashley Kiel, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 78, Iss. 4, pp. 853-861
Closed Access | Times Cited: 5
Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis
Ryoji Taniguchi, Ryusuke Nambu, Kayoko Ichimura, et al.
Clinical Journal of Gastroenterology (2025) Vol. 18, Iss. 2, pp. 278-281
Closed Access
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
Shlomi Cohen, Elizabeth Spencer, Michael Dolinger, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access
National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease
Brad D. Constant, Jeremy Adler, Benjamin D. Gold, et al.
JPGN Reports (2025)
Open Access
Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—Children and Adolescents with IBD
Wael El‐Matary, Matthew Carroll, Colette Deslandres, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S35-S44
Open Access | Times Cited: 12
An update on the safety of long-term vedolizumab use in inflammatory bowel disease
Sailish Honap, Patrick Netter, Silvio Danese, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 9, pp. 767-776
Open Access | Times Cited: 9
Dual biological therapy and small molecules in pediatric inflammatory bowel disease
Francesca Penagini, Luisa Lonoce, Luisa Abbattista, et al.
Pharmacological Research (2023) Vol. 196, pp. 106935-106935
Open Access | Times Cited: 9
Advancements in the management of pediatric inflammatory bowel disease
Jonathan O'Donnell, Sonia Thomas, Eric I. Benchimol
Expert Review of Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
The Future of Advanced Therapies for Pediatric Crohn’s Disease
Julie Gallagher, Joel R. Rosh, Benjamin Sahn
Pediatric Drugs (2023) Vol. 25, Iss. 6, pp. 621-633
Closed Access | Times Cited: 4
Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease
Yogi Chopra, Karol Acevedo Viales, Aleixo M. Muise, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 5, pp. 546.e1-546.e7
Closed Access | Times Cited: 1
Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper
Aarti Sawant‐Basak, Shweta Urva, Jatinder Kaur Mukker, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 4, pp. 902-913
Open Access | Times Cited: 1
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress
Debora Curci, Marianna Lucafò, Giuliana Decorti, et al.
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies
M. Classen, André Hoerning
Children (2023) Vol. 10, Iss. 4, pp. 634-634
Open Access | Times Cited: 3
Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan
Koji Yokoyama, Yoko Yamamoto, Ryusuke Nambu, et al.
Journal of Gastroenterology and Hepatology (2023) Vol. 38, Iss. 7, pp. 1107-1115
Open Access | Times Cited: 3
Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review
Anat Yerushalmy‐Feler, Caroline Brauner, Shlomi Cohen
Pediatric Drugs (2023) Vol. 25, Iss. 5, pp. 489-498
Closed Access | Times Cited: 3
The State of Clinical Trials in Pediatric Inflammatory Bowel Disease
Jeffrey S. Hyams, Richard K. Russell
Gastroenterology Clinics of North America (2023) Vol. 52, Iss. 3, pp. 589-597
Closed Access | Times Cited: 3
Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting
Maria Hemming‐Harlo, Laura Merras‐Salmio, Anne Nikkonen, et al.
European Journal of Pediatrics (2023) Vol. 183, Iss. 1, pp. 313-322
Open Access | Times Cited: 2
Variation in access and prescription of vedolizumab and ustekinumab in paediatric patients with inflammatory bowel disease: a UK-wide study
Marcus Karl‐Heinz Auth, James J. Ashton, Kelsey Jones, et al.
Archives of Disease in Childhood (2023) Vol. 108, Iss. 12, pp. 994-998
Open Access | Times Cited: 2
Considerations in Paediatric and Adolescent Inflammatory Bowel Disease
S Vuijk, A Camman, Lissy de Ridder
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. Supplement_2, pp. ii31-ii45
Open Access
Treating paediatric Crohn’s disease is challenging but new treatments hold promise
Tina Nie
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 3, pp. 121-126
Closed Access
Updates In The Management Of Pediatric Inflammatory Bowel Disease
Nicholas Carman
Canadian IBD Today (2024)
Open Access
Page 1 - Next Page

Scroll to top